There exists an active metabolite of Relpax as a result of N-demethylation. The half-life of the active metabolite is for a longer time than Relpax (about thirteen hours), but its plasma focus reaches only ten% to twenty% that with the parent drug. Hence, the active metabolite is not likely to add on the therapeutic effects of Relpax.medication ove